The recent published papers and received awards are presented below

2021

Medicine (Baltimore). 2021 Feb 19;100(7):e24738

A machine-learning based approach to quantify fine crackles in the diagnosis of interstitial pneumonia: A proof-of-concept study.

Horimasu Y, Ohshimo S, Yamaguchi K, Sakamoto S, Masuda T, Nakashima T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Sadamori T, Shime N, Hattori N

Eur J Clin Microbiol Infect Dis. 2021 Apr;40(4):871-877

Concomitant emphysema might increase the false-negative rate of urinary antigen tests in patients with pneumococcal pneumonia: results from a retrospective study.

Kobayashi E, Yamaguchi K, Nagaoka R, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Yokozaki M, Ohge H, Hamada H, Hattori N

Cancer Sci. 2021 Jan;112(1):369-379

Clinical significance of BIM deletion polymorphism in chemoradiotherapy for non-small cell lung cancer.

Wakabayashi Y, Masuda T, Fujitaka K, Nakashima T, Okumoto J, Shimoji K, Nishimura Y, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Ohshimo S, Hamada H, Hattori N

2020

JAMA Netw Open. 2020 Nov 2;3(11):e2022906

Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers.

Shimoji K, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Takeno S, Hide M, Teishima J, Ohdan H, Hattori N

Respir Med. 2020 Oct;172:106131

Serum high-mobility group box 1 as a predictive marker for cytotoxic chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease.

Nakao S, Yamaguchi K, Iwamoto H, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N

Respir Res. 2020 Jun 11;21(1):145

Reduced Endogenous Secretory RAGE in Blood and Bronchoalveolar Lavage Fluid Is Associated With Poor Prognosis in Idiopathic Pulmonary Fibrosis.

Yamaguchi K, Iwamoto H, Mazur W, Miura S, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N

J Thorac Dis. 2020 Mar;12(3):1079-1084

Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer.

Masuda T, Fujitaka K, Ishikawa N, Nakano K, Yamasaki M, Kitaguchi S, Masuda K, Yamaguchi K, Sakamoto S, Horimasu Y, Kawase S,Miyamoto S, Nakashima T, Iwamoto H, Shiota N, Senoo T, Awaya Y, Kondo T, Yoshida T, Hamada H, Murakami I, Hattori N

Int J Clin Oncol. 2020 Jan;25(1):74-81

Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer.

Nakanishi Y, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Mimae T, Nakashima T, Miyamoto S, Tsutani Y, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N

Respirology. 2020 Mar;25(3):275-280

Serum high-mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis.

Yamaguchi K, Iwamoto H, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N

2019

Am J Respir Crit Care Med. 2019 Oct 15;200(8):1032-1044

Role of B7H3/IL-33 Signaling in Pulmonary Fibrosis-induced Profibrogenic Alterations in Bone Marrow.

Nakashima T, Liu T, Hu B, Wu Z, Ullenbruch M, Omori K, Ding L, Hattori N, Phan SH

J Clin Med. 2019 Nov 24;8(12)

Baseline High-Resolution CT Findings Predict Acute Exacerbation of Idiopathic Pulmonary Fibrosis: German and Japanese Cohort Study.

Hirano C, Ohshimo S, Horimasu Y, Iwamoto H, Fujitaka K, Hamada H, Kohno N, Komoto D, Awai K, Shime N, Bonella F, Guzman J, Kühl H, Costabel U, Hattori N

Anticancer Res. 2019 Oct;39(10):5725-5731

Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer.

Nakao S, Yamaguchi K, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N

Respiration. 2019;98(3):212-220

C-C Motif Chemokine Ligand 15 May Be a Useful Biomarker for Predicting the Prognosis of Patients with Chronic Hypersensitivity Pneumonitis.

Watanabe M, Horimasu Y, Iwamoto H, Yamaguchi K, Sakamoto S, Masuda T, Nakashima T, Miyamoto S, Ohshimo S, Fujitaka K, Hamada H, Kohno N, Hattori N

Respir Investig. 2019 Sep;57(5):451-459

Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.

Nakanishi Y, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Tsutani Y, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N

Respir Med. 2019 Jun;152:44-50

Comparison of anti-aminoacyl-tRNA synthetase antibody-related and idiopathic non-specific interstitial pneumonia.

Shioya S, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Senoo T, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N

Free Radic Biol Med. 2019 May 20;136:52-59

Suplatast tosilate reduces radiation-induced lung injury in mice through suppression of oxidative stress.

Izumi Y, Nakashima T, Masuda T, Shioya S, Fukuhara K, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N

J Cell Mol Med. 2019 Apr;23(4):2984-2994

Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts.

Masuda T, Nakashima T, Namba M, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N

Medicine (Baltimore). 2019 Feb;98(5):e14296

High preoperative C-reactive protein level is a risk factor for acute exacerbation of interstitial lung disease after non-pulmonary surgery.

Takao S, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Hattori N

Intern Med. 2019 Apr 1;58(7):915-920

Performance Status Is a Risk Factor for Depression before the Diagnosis of Lung Cancer Patients.

Miwata K, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N

2018

Exp Ther Med. 2018 Dec;16(6):5236-5242

Effects of Hochuekkito combined with pulmonary rehabilitation in patients with chronic obstructive pulmonary disease.

Hamada H, Sekikawa K, Murakami I, Aimoto K, Kagawa K, Sumigawa T, Okusaki K, Dodo T, Awaya Y, Watanabe M, Kondo K, Ogawa T, Yamamoto H, Hattori N

Medicine (Baltimore). 2018;97:e13542

Serial measurements of KL-6 for monitoring activity and recurrence of interstitial pneumonia with anti-aminoacyl-tRNA synthetase antibody: A retrospective cohort study.

Yamaguchi K, Iwamoto H, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Kohno N, Hattori N

Cancer Lett. 2018 pii: S0304-3835(18)30652-9

Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1.

Namba M, Hattori N, Hamada H, Yamaguchi K, Okamoto Y, Nakashima T, Masuda T, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Kohno N

Mol Clin Oncol. 2018 Nov;9(5):539-544

Alternate-day administration of S-1 for elderly patients with advanced non-small-cell lung carcinoma: A prospective feasibility study.

Masuda T, Watanabe M, Fujitaka K, Hamai K, Ishikawa N, Doi M, Kitaguchi S, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Senoo T, Iwamoto H, Hamada H, Hattori N

Exp Ther Med. 2018;16:3070-3076

Plasminogen activator inhibitor-1 serves an important role in radiation-induced pulmonary fibrosis.

Shioya S, Masuda T, Senoo T, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Hattori N

In Vivo. 2018;32:1155-1160

Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study.

Yamaguchi K, Masuda T, Fujitaka K, Miwata K, Sakamoto S, Horimasu Y, Hamai K, Miyamoto S, Nakashima T, Okamoto Y, Iwamoto H, Ishikawa N, Miyata Y, Okada M, Hamada H, Hattori N

Mol Ther Nucleic Acids. 2018;12:698-706

Intratracheal Administration of siRNA Dry Powder Targeting Vascular Endothelial Growth Factor Inhibits Lung Tumor Growth in Mice.

Miwata K, Okamoto H, Nakashima T, Ihara D, Horimasu Y, Masuda T, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Shibata A, Ito T, Okuda T, Hattori N

Eur Respir J. 2018. pii: 1701610

Aminopeptidase N/CD13 as a Potential Therapeutic Target in Malignant Pleural Mesothelioma.

Otsuki T, Nakashima T, Hamada H, Takayama Y, Akita S, Masuda T, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Miyata Y, Miyake M, Kohno N, Okada M, Hattori N

Cancer Chemother Pharmacol. 2018;81:131-139

The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer

Masuda T, Hirano C, Horimasu Y, Nakashima T, Miyamoto S, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N

2017

Oncotarget. 2017;8:94382-92

AGER rs2070600 polymorphism elevates neutrophil-lymphocyte ratio and mortality in metastatic lung adenocarcinoma

Yamaguchi K, Iwamoto H, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N

BMC Med Genet. 2017;18:88

Gene expression profiling of idiopathic interstitial pneumonias (IIPs): identification of potential diagnostic markers and therapeutic targets

Horimasu Y, Ishikawa N, Taniwaki M, Yamaguchi K, Hamai K, Iwamoto H, Ohshimo S, Hamada H, Hattori N, Okada M, Arihiro K, Ohtsuki Y, Kohno N

BMC Cancer. 2017;17:263

MUC1 in lung adenocarcinoma: cross-sectional genetic and serological study

Horimasu Y, Ishikawa N, Tanaka S, Hirano C, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N, Kohno N

Clin Lung Cancer. 2017 in press

Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer.

Sakamoto S, Yamada T, Terazaki Y, Yoshiyama K, Sugawara S, Takamori S, Matsueda S, Shichijo S, Yamada A, Noguchi M, Itoh K, Hattori N, Kohno N, Sasada T

Respirology. 2017;22:965-71

AGER gene polymorphisms and soluble receptor for advanced glycation end product in patients with idiopathic pulmonary fibrosis

Yamaguchi K, Iwamoto H, Horimasu Y, Ohshimo S, Fujitaka K, Hamada H, Mazur W, Kohno N, Hattori N

Cancer Sci. 2017;108:598-603

Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11+ or -A33+ allele

Sakamoto S, Matsueda S, Takamori S, Toh U, Noguchi M, Yutani S, Yamada A, Shichijo S, Yamada T, Suekane S, Kawano K, Naitou M, Sasada T, Hattori N, Kohno N, Itoh K

Free Radic Biol Med. 2017;106:1-9

Suplatast tosilate protects the lung against hyperoxic lung injury by scavenging hydroxyl radicals

Fukuhara K, Nakashima T, Abe M, Masuda T, Hamada H, Iwamoto H, Fujitaka K, Kohno N, Hattori N

2016

Respir Med 2017;123:105-109

FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosis

Hirano C, Ohshimo S, Horimasu Y, Iwamoto H, Fujitaka K, Hamada H, Hattori N, Shime N, Bonella F, Guzman J, Costabel U, Kohno N

Respirology. 2017;22:86-92

Clinically remitted childhood asthma is associated with airflow obstruction in middle-aged adults

Omori K, Iwamoto H, Yamane T, Nakashima T, Haruta Y, Hattori N, Yokoyama A, Kohno N

Int J Chron Obstruct Pulmon Dis. 2016;11:2457-2465

Characterization of sputum biomarkers for asthma-COPD overlap syndrome

Gao J, Iwamoto H, Koskela J, Alenius H, Hattori N, Kohno N, Laitinen T, Mazur W, Pulkkinen V

PLoS One. 2016;11:e0162672

Sputum Leucine-Rich Alpha-2 Glycoprotein as a Marker of Airway Inflammation in Asthma

Honda H, Fujimoto M, Miyamoto S, Ishikawa N, Serada S, Hattori N, Nomura S, Kohno N, Yokoyama A, Naka T

Occup Environ Med. in press

Mustard gas exposure and mortality among retired workers at a poisonous gas factory in Japan: a 57-year follow-up cohort study

Mukaida K, Hattori N, Iwamoto H, Onari Y, Nishimura Y, Kondoh K, Akita T, Tanaka J, Kohno N

Respirology. in press

Clinically remitted childhood asthma is associated with airflow obstruction in middle-aged adults

Omori K, Iwamoto H, Yamane T, Nakashima T, Haruta Y, Hattori N, Yokoyama A, Kohno N

Dis Markers. 2016;2016:4759040

Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis

Hamai K, Iwamoto H, Ishikawa N, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N, Kohno N

Cancer Res. 2016;76:3285-94

Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma

Takayama Y, Hattori N, Hamada H, Masuda T, Omori K, Akita S, Iwamoto H, Fujitaka K, Kohno N

Inhal Toxicol. 2016;28:343-8

Long-term pulmonary complications of chemical weapons exposure in former poison gas factory workers

Nishimura Y, Iwamoto H, Ishikawa N, Hattori N, Horimasu Y, Ohshimo S, Fujitaka K, Kondo K, Hamada H, Awai K, Kohno N

PLoS One. 2016; 11:e0148969

Inhibition of Plasminogen Activator Inhibitor-1 Attenuates Transforming Growth Factor-β-Dependent Epithelial Mesenchymal Transition and Differentiation of Fibroblasts to Myofibroblasts

Omori K, Hattori N, Senoo T, Takayama Y, Masuda T, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Kohno N

2015

BMC Infect Dis. 2015; 15:426

Clinical characteristics and risk factors of enterococcal infections in Nagasaki, Japan: a retrospective study

Kajihara T, Nakamura S, Iwanaga N, Oshima K, Takazono T, Miyazaki T, Izumikawa K, Yanagihara K, Kohno N, Kohno S

Hum Vaccin Immunother. 2015; 11:2784-9

Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination

Sakamoto S, Yoshitomi M, Yutani S, Terazaki Y, Yoshiyama K, Ioji T, Matsueda S, Yamada A, Takamori S, Itoh K, Hattori N, Kohno N, Sasada T

Cancer Sci. 2015; 106:1257-63

Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele

Sakamoto S, Matsueda S, Takamori S, Toh U, Noguchi M, Yutani S, Yamada A, Shichijo S, Yamada T, Suekane S, Kawano K, Sasada T, Hattori N, Kohno N, Itoh K

Pharm Res. 2015; 32:3877-85

Histological Quantification of Gene Silencing by Intratracheal Administration of Dry Powdered Small-Interfering RNA/Chitosan Complexes in the Murine Lung

Ihara D, Hattori N, Horimasu Y, Masuda T, Nakashima T, Senoo T, Iwamoto H, Fujitaka K, Okamoto H, Kohno N

Cancer Sci. 2015l; 106:921-8

MT95-4, a fully humanized antibody raised against aminopeptidase N, reduces tumor progression in a mouse mode

Akita S, Hattori N, Masuda T, Horimasu Y, Nakashima T, Iwamoto H, Fujitaka K, Miyake M, Kohno N

Int J Chron Obstruct Pulmon Dis. 2015; 10:185-92

Airway inflammation in Japanese COPD patients compared with smoking and nonsmoking controls

Ishikawa N, Hattori N, Kohno N, Kobayashi A, Hayamizu T, Johnson M

Respirology. 2015; 20:439-44

MUC5B promoter polymorphism in Japanese patients with idiopathic pulmonary fibrosis

Horimasu Y, Ohshimo S, Bonella F, Tanaka S, Ishikawa N, Hattori N, Kohno N, Guzman J, Costabel U

Respirology. 2015; 20:87-94

Effect of increasing respiratory rate on airway resistance and reactance in COPD patients

Nakagawa M, Hattori N, Haruta Y, Sugiyama A, Iwamoto H, Ishikawa N, Fujitaka K, Murai H, Tanaka J, Kohno N

2014

Respir Med. 2014; 108:1031-9

Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis

Ohshimo S, Ishikawa N, Horimasu Y, Hattori N, Hirohashi N, Tanigawa K, Kohno N, Bonella F, Guzman J, Costabel U

BMC Med Genet. 2014;15:4

Differences in serum SP-D levels between German and Japanese subjects are associated with SFTPD gene polymorphisms

Horimasu Y, Hattori N, Ishikawa N, Tanaka S, Bonella F, Ohshimo S, Guzman J, Costabel U, Kohno N

2013

Mol Cancer Res. 2013; 11:937-51

RASEF is a novel diagnostic biomarker and a therapeutic target for lung cancer.

Oshita H, Nishino R, Takano A, Fujitomo T, Aragaki M, Kato T, Akiyama H, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y.

Respir Med. 2013; 107:875-82

Characteristics of inspiratory and expiratory reactance in interstitial lung disease

Sugiyama A, Hattori N, Haruta Y, Nakamura I, Nakagawa M, Miyamoto S, Onari Y, Iwamoto H, Ishikawa N, Fujitaka K, Murai H, Kohno N

Mol Cancer Ther. 2013; 12:2378-88

SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis.

Masuda T, Hattori N, Senoo T, Akita S, Ishikawa N, Fujitaka K, Haruta Y, Murai H, Kohno N

2012

Hiroshima J Med Sci 2012; 61:29-36

Cigarette smoking decreases dynamic inspiratory capacity during maximal exercise in patients with type 2 diabetes

Kitahara Y, Hattori N, Yokoyama A, Yamane K, Sekikawa K, Inamizu T, Kohno N.

Int J Cancer. 2012; 130:377-87

Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected non-small cell lung cancer.

Tanaka S, Hattori N, Ishikawa N, Shoda H, Takano A, Nishino R, Okada M, Arihiro K, Inai K, Hamada H, Yokoyama A, Kohno N.

Pathobiology 2012; 79:24-33

Interferon (alpha, Beta and omega) receptor 2 is a prognostic biomarker for lung cancer.

Tanaka S, Hattori N, Ishikawa N, Horimasu Y, Deguchi N, Takano A, Tomoda Y, Yoshioka K, Fujitaka K, Arihiro K, Okada M, Yokoyama A, Kohno N.

Respir Med 2012; 106:1756-64

Different MUC1 gene polymorphisms in German and Japanese ethnicities affect serum KL-6 levels.

Horimasu Y, Hattori N, Ishikawa N, Kawase S, Tanaka S, Yoshioka K, Yokoyama A, Kohno N, Bonella F, Guzman J, Ohshimo S, Costabel U.

Respir Investig. 2012; 50:3-13

Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases.

Ishikawa N, Hattori N, Yokoyama A, Kohno N.

Immunol Allergy Clin North Am 2012; 32:537-56

Hypersensitivity pneumonitis.

Ohshimo S, Bonella F, Guzman J, Costabel U.

2011

Oncol Lett. 2011; 2:167-170

Phase I study of docetaxel plus S-1 combination chemotherapy for recurrent non-small cell lung cancer

Fujitaka K, Hattori N, Senoo T, Iwamoto H, Ohshimo S, Kanehara M, Ishikawa N, Haruta Y, Murai H, Kohno N

Am J Epidemiol. 2011; 173:659-66

Effect of mustard gas exposure on incidence of lung cancer: a longitudinal study

Doi M, Hattori N, Yokoyama A, Onari Y, Kanehara M, Masuda K, Tonda T, Ohtaki M, Kohno N

Respir Res. 2011; 12:32

KL-6 concentration in pulmonary epithelial lining fluid is a useful prognostic indicator in patients with acute respiratory distress syndrome

Kondo T, Hattori N, Ishikawa N, Murai H, Haruta Y, Hirohashi N, Tanigawa K, Kohno N

Phytomedicine. 2011; 18:625-9

A pilot study of the multiherb Kampo medicine bakumondoto for cough in patients with chronic obstructive pulmonary disease

Mukaida K, Hattori N, Kondo K, Morita N, Murakami I, Haruta Y, Yokoyama A, Kohno N

J Asthma. 2011; 48:907-13

Association of airway inflammation with asthma control level evaluated by the asthma control test

Shiota N, Yokoyama A, Haruta Y, Hattori N, Kohno N

Chest. 2011; 139:296-304

Mucins carrying selectin ligands as predictive biomarkers of disseminated intravascular coagulation complication in ARDS

Nakashima T, Yokoyama A, Inata J, Ishikawa N, Haruta Y, Hattori N, Kohno N

Allergol Int. 2011; 60:299-304

Chronic hepatitis C virus infection is associated with more severe asthma

Nakashima T, Yokoyama A, Ohnishi H, Yamasaki M, Shiode M, Haruta Y, Hattori N, Hozawa S, Yamakido H, Kohno N

Am J Physiol Lung Cell Mol Physiol. 2011; 301:L908-16

Intra-airway administration of small interfering RNA targeting plasminogen activator inhibitor-1 attenuates allergic asthma in mice

Miyamoto S, Hattori N, Senoo T, Onari Y, Iwamoto H, Kanehara M, Ishikawa N, Fujitaka K, Haruta Y, Murai H, Yokoyama A, Kohno N

Respir Res. 2011; 12:97

Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease

Kawase S, Hattori N, Ishikawa N, Horimasu Y, Fujitaka K, Furonaka O, Isobe T, Miyoshi S, Hamada H, Yamane T, Yokoyama A, Kohno N

Cancer Chemother Pharmacol. 2011; 67:1465-9

Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy

Masuda T, Hattori N, Hamada A, Iwamoto H, Ohshimo S, Kanehara M, Ishikawa N, Fujitaka K, Haruta Y, Murai H, Kohno N

Respiration. 2011; 82:10-8

Levels of surfactant proteins A and D and KL-6 are elevated in the induced sputum of chronic obstructive pulmonary disease patients: a sequential sputum analysis

Ishikawa N, Hattori N, Tanaka S, Horimasu Y, Haruta Y, Yokoyama A, Kohno N, Kinnula VL

Clin Cancer Res. 2011; 17:6272-86

Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer

Nishino R, Takano A, Oshita H, Ishikawa N, Akiyama H, Ito H, Nakayama H, Miyagi Y, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y

Clin Cancer Res. 2011; 17:7712-22

Chondrolectin is a novel diagnostic biomarker and a therapeutic target for lung cancer

Masuda K, Takano A, Oshita H, Akiyama H, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y

Hiroshima J Med Sci 2011; 60:7-9

Regression of a primary pulmonary adenocarcinoma after zoledronic acid monotherapy

agao S, Hattori N, Fujitaka K, Iwamoto H, Ohshimo S, Kanehara M, Ishikawa N, Haruta Y, Murai H, Kohno N